Literature DB >> 19398595

Limited value of testing for intrinsic factor antibodies with negative gastric parietal cell antibodies in pernicious anaemia.

S Khan1, C Del-Duca, E Fenton, S Holding, J Hirst, P C Doré, W A C Sewell.   

Abstract

BACKGROUND: The appropriate testing strategy for diagnosing pernicious anaemia using gastric parietal cell (GPC) and/or intrinsic factor antibodies (IFA) is controversial. Intrinsic factor antibodies are found in only about 70% of cases. Indirect immunofluorescence screening for gastric parietal cell antibodies is more sensitive, labour intensive, and less specific.
METHODS: The frequency of antibody positivity (IFA and/or GPC) was retrospectively examined in patients tested for both autoantibodies over a three-year period. It was investigated whether B12 levels were related to antibody status. These findings were validated in a prospective study of IFA in 91 GPC negative patients with low B12 levels.
RESULTS: Of 847 samples identified in the retrospective study, 4 (0.47%) were positive for only intrinsic factor antibodies, 731 (86.3%) positive for GPC alone, and 112 (13.2%) for both. Student t test on log-transformed data showed B12 levels had no bearing on autoantibody status. 91 consecutive patients with low B12 levels were tested for both autoantibodies; all were negative for gastric parietal cell antibodies. Only one sample was positive for intrinsic factor antibody using the porcine intrinsic factor assay, but was negative by a human recombinant intrinsic factor-based ELISA.
CONCLUSIONS: This study provides evidence that testing for gastric parietal cell antibodies is an appropriate screening test for pernicious anaemia, with intrinsic factor antibodies reserved for confirmatory testing or in patients with other autoantibodies that mask the GPC pattern; B12 levels are not related to autoantibody status.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19398595     DOI: 10.1136/jcp.2008.060509

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

Review 1.  Cutting edge issues in autoimmune gastritis.

Authors:  Ban-Hock Toh; James Chan; Tin Kyaw; Frank Alderuccio
Journal:  Clin Rev Allergy Immunol       Date:  2012-06       Impact factor: 8.667

Review 2.  Pathophysiology and laboratory diagnosis of pernicious anemia.

Authors:  Ban-Hock Toh
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 3.  A short review of malabsorption and anemia.

Authors:  Fernando Fernández-Bañares; Helena Monzón; Montserrat Forné
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

Review 4.  Autoimmune atrophic gastritis: current perspectives.

Authors:  Artem Minalyan; Jihane N Benhammou; Aida Artashesyan; Michael S Lewis; Joseph R Pisegna
Journal:  Clin Exp Gastroenterol       Date:  2017-02-07

Review 5.  The Many Faces of Cobalamin (Vitamin B12) Deficiency.

Authors:  Bruce H R Wolffenbuttel; Hanneke J C M Wouters; M Rebecca Heiner-Fokkema; Melanie M van der Klauw
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2019-05-27

6.  Proteomics signature of autoimmune atrophic gastritis: towards a link with gastric cancer.

Authors:  Ombretta Repetto; Valli De Re; Paolo Giuffrida; Marco Vincenzo Lenti; Raffaella Magris; Marino Venerito; Agostino Steffan; Antonio Di Sabatino; Renato Cannizzaro
Journal:  Gastric Cancer       Date:  2021-02-23       Impact factor: 7.370

7.  Intrinsic factor autoantibodies by luminescent immuno-precipitation system in patients with corpus atrophic gastritis.

Authors:  Ilaria Marzinotto; Ludovica Dottori; Francesca Baldaro; Emanuele Dilaghi; Cristina Brigatti; Elena Bazzigaluppi; Gianluca Esposito; Howard W Davidson; Lorenzo Piemonti; Vito Lampasona; Edith Lahner
Journal:  J Transl Autoimmun       Date:  2021-11-01

Review 8.  Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management.

Authors:  Sheila D Rustgi; Priyesha Bijlani; Shailja C Shah
Journal:  Therap Adv Gastroenterol       Date:  2021-08-31       Impact factor: 4.409

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.